Status:
COMPLETED
Effect of Hepatitis C Clearance on Insulin Resistance
Lead Sponsor:
Alexandria University
Conditions:
Insulin Resistance
Hepatitis C
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Chronic hepatitis C infection has been linked to insulin resistance, which is the essential component of metabolic syndrome and type 2 diabetes mellitus. Resistin; an adipokine, has been demonstrated ...
Detailed Description
the link between hepatitis C infection and insulin resistance has been established. Insuli resistance has been linked to poor response to interferon based therapy. recently, direct acting antiviral dr...
Eligibility Criteria
Inclusion
- Hepatitis C treatment-naïve;
- Non-diabetic patients.
Exclusion
- Seropositivity for hepatitis B virus infection;
- Diabetes mellitus;
- Bbody mass index ≥ 30 Kg/M\*2;
- History of alcohol consumption;
- Endocrinopathies that may affect the glycemic homeostasis;
- Other known causes of chronic liver disease; Hepatic decompensation \[defined as history of gastrointestinal bleeding (melena and /or hematemesis), jaundice, coagulopathy, hepatic encephalopathy, and/or ascites\]; bleeding diathesis;
- Connective tissue diseases;
- Autoimmune diseases;
- Cardiac, respiratory or renal disease.
- Patient receiving immuno-modulatory therapy or drugs that affect the blood glucose levels such as steroids or beta-blockers.
Key Trial Info
Start Date :
October 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2019
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04457050
Start Date
October 30 2017
End Date
December 30 2019
Last Update
July 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Alexandria, Egypt, 21521